ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
The Modern Marketing Maze
Read ICON expert Chuck Stevens' comments on how he and his team are supporting patient/consumer access in this recent PharmaTimes article.
MolecularMD Profiled as CDx Developer Making a Mark
MolecularMD is profiled as one of eight Companion Diagnostic (CDx) developers to watch for their track record, including recent activity in the field, in this July 2019 Clinical OMICs article.
A Small Biotech Takes On Some Big Clinical Trial Challenges
Clinical Leader discusses how Clinical RM (now ICON GPHS) was selected to conduct a chlamydia study, AMPREVENCE, based on recognized experience in STD trials.
Moving Beyond a Buzzword: How Small- to Mid-sized Biotechs Can Adopt Patient Centricity in Oncology Trials
Read BioCentury's latest media article written by ICON's Lucy Clossick Thomson & Susan Campbell, discussing biotechs' use for patient engagement to improve cancer trial recruitment.
America's Best Employers for Women
ICON has been recognised in Forbes' 2019 list of America’s Best Employers for Women.
10 Professionals Predict the Future of Clinical Trials
Read ICON expert Sarah Ikard's take on the innovative role patient centricity may play in the evolution of future trials here.
The Long Journey Towards Patient Centricity
ICON experts discuss the evolution of patient reported outcomes & the role of patient outcome research in informing payers, patients, clinicians & regulators.
Adoptive Cell Transfer (ACT) Clinical Trials: The Long Road
ICON's Martin Lachs & Brandon Fletcher discuss ACT clinical trials in this July 2019 DDN News article.
Leveraging Novel Therapeutics & Diagnostic Assays
Marisa Pearce at Molecular MD, an ICON company, argues that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.
Technology the Key for Improving Trial Efficiencies & Retention
Learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.